fda semaglutide compounding enforcement november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA issues warning about some

The insurance targeting Zepbound may be much more limited, because the drug is effective only in treating overweight and obesity, the majority of insurers do not cover medications for weight loss

Ozempic (semaglutide) is a GLP-1 receptor agonist used to treat Type 2 diabetes, but with its list price exceeding $1,300 per pen, insurance coverage matters

Standard GLP-1 protocols begin at lower doses and increase every 1 to 4 weeks, allowing your gastrointestinal system time to adjust

Composition of Retatrutide Retatrutide is composed of a specific amino acid sequence engineered to bind to multiple hormone receptors

In late-stage trials, people taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks , and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control